<?xml version="1.0" encoding="UTF-8"?>
<p id="Par51">Anti-complement C5 therapy with eculizumab is reported to be a potential key player in treatment of severe cases of COVID-19 [
 <xref ref-type="bibr" rid="CR95">95</xref>]. Some studies reported that the use of corticosteroids might speed up improvement from COVID-19 [
 <xref ref-type="bibr" rid="CR96">96</xref>]. However, it is also reported that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may worsen conditions in SARS-CoV2 patients [
 <xref ref-type="bibr" rid="CR97">97</xref>]. Therefore, use of corticosteroids or Janus kinase (JAK) blockers need to be reconsidered in cases with hyperinflammation [
 <xref ref-type="bibr" rid="CR98">98</xref>]. One study indicated that Lianhuaqingwen, a conventional Chinese medicine formula significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines [
 <xref ref-type="bibr" rid="CR99">99</xref>].
</p>
